Trials / Completed
CompletedNCT04324918
Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis
Efficacy and Safety of HCP1102 in Patients With Perennial Allergic Rhinitis : A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 174 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy and safety of HCP1102 in patients with perennial allergic rhinitis : A randomized, double-blind, active-controlled, multicenter phase 3 clinical trial
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HCP1102 | The participants will receive tretment of HCP1102(combination of Montelukast + Levocetrizine), orally, once daily for 4weeks. |
| DRUG | HGP1408 | The participants will receive tretment of HGP1408(Levocetrizine), orally, once daily for 4weeks. |
Timeline
- Start date
- 2018-10-23
- Primary completion
- 2019-06-24
- Completion
- 2019-06-24
- First posted
- 2020-03-27
- Last updated
- 2020-03-27
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04324918. Inclusion in this directory is not an endorsement.